Fig. 2.
Fig. 2. TFI. / (A) The 2-year TFI was 38% in the BM group () versus 13% in the PBPC group (---) (P < .001). (B) The 2-year TFI in patients with RAEB at last evaluation was 41% with BM () versus 16% with PBPCs (---) (P = .026). (C) The 2-year TFI in patients with RAEB-t at last evaluation was 55% with BM () versus 14% with PBPCs (---) (P < .001). (D) The 2-year TFI in patients with intermediate-2 or high IPSS score was 6% with PBPCs (—) versus 45% with BM () (P < .003). The 2-year TFI in patients with low or intermediate-1 IPSS score was 0% with PBPCs (····) versus 26% with BM (---) (P = .046).

TFI.

(A) The 2-year TFI was 38% in the BM group () versus 13% in the PBPC group (---) (P < .001). (B) The 2-year TFI in patients with RAEB at last evaluation was 41% with BM () versus 16% with PBPCs (---) (P = .026). (C) The 2-year TFI in patients with RAEB-t at last evaluation was 55% with BM () versus 14% with PBPCs (---) (P < .001). (D) The 2-year TFI in patients with intermediate-2 or high IPSS score was 6% with PBPCs () versus 45% with BM () (P < .003). The 2-year TFI in patients with low or intermediate-1 IPSS score was 0% with PBPCs (····) versus 26% with BM (---) (P = .046).

Close Modal

or Create an Account

Close Modal
Close Modal